Saverymuttu S H, Gupta S, Keshavarzian A, Donovan B, Hodgson H J
Digestion. 1986;33(2):89-91. doi: 10.1159/000199279.
A short-term double-blind controlled trial has been performed comparing a slow-release 5'-aminosalicylic acid (5-ASA) tablet (Pentasa) with placebo in the outpatient treatment of mild and moderate active Crohn's colitis. The disease activity was measured objectively by quantitation of the faecal excretion of 111In-labelled autologous granulocytes, which directly reflects gut inflammation. Twelve patients were randomized to receive either Pentasa or placebo. After 10 days of treatment faecal granulocyte excretion fell in all patients receiving 5-ASA, while no consistent change was found in the placebo group. These results suggest that this slow-release preparation of 5-ASA should be tested in larger controlled therapeutic trials over a longer period of time.
已开展一项短期双盲对照试验，比较缓释型5-氨基水杨酸（5-ASA）片剂（颇得斯安）与安慰剂用于门诊治疗轻中度活动性克罗恩结肠炎的效果。通过对111In标记的自体粒细胞粪便排泄量进行定量来客观测量疾病活动度，这直接反映肠道炎症。12名患者被随机分组，分别接受颇得斯安或安慰剂治疗。治疗10天后，所有接受5-ASA治疗的患者粪便粒细胞排泄量均下降，而安慰剂组未发现一致变化。这些结果表明，这种5-ASA缓释制剂应在更大规模的长期对照治疗试验中进行测试。
